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Fig. 1. Effect of nifedipine on diastolic filling rate. Post-nifedipine
studies were conducted 20 minutes after 10 mg sublingual
nifedipine.
The results are summarised in Tables I and 11 and Figs I and
2. The acute blood pressure changes during the administration
of nifedipine together with changes in the ejection fraction
have already been published elsewhere.s The chief findings of
note were as follows: nifedipine, in addition to reducing
systolic and diastolic blood pressure and slightly enhancing the
ejection fraction, also increased the average diastolic filling
rate (Fig. I). There were no changes in the time to the peak
filling rate, nor in indices of systolic phase function such as
peak systolic ejection rate or mean systolic ejection rate. With
diltiazem the blood pressure decreased (Fig. 2) during the
period of observation, with the first systolic decrease occurring
at 30 minutes (borderline statistical significance); 50 minutes
was required for the diastolic and the systolic pressures to
reach statistical significance by when they had fallen from
initial systolic values of 187 ± 8,6 mmHg (means ± SEM: N
= 11) to 161 ± 7,3 mmHg, while the fall in diastolic values
was from 117 ± 5,2 mmHg to 102 ± 6,0 mmHg (P < 0,01
systolic; P < 0,05 diastolic). Diltiazem also increased the
ejection fraction (Fig. 3) and the peak diastolic filling rate,
while leaving the indices of systolic function unchanged (Table
11).
For comparison the effects of diltiazem on a group of 7
patients with hypertrophic cardiomyopathy were also studied
(Table Ill). There were no changes in the ejection fraction
(control 76%), or in the heart rate (control 76/min), or in the
time to peak filling rate (0,35 s). However, with diltiazem
the peak diastolic filling rate rose from 2,67 ± 0,39 end
diastolic volume (EDV)/s to 3,30 ± 0,33 EDV/s (P < 0,01).
Averagediastolic filling rates were marginally increased from
1,24 ± 0,16 EDVIs to 1,40 ± 0,15 EDVIs (borderline NS, P
value 0,(6).
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Calcium antagonists are known to decrease blood pressure
acutely and chronically in hypertensive patients with hyper-
tensive heart disease, and also to improve their systolic
function. However, disorders of diastolic function may occur
early in hypertensive heart disease. The improvement of
diastolic function by nifedipine and diltiazem is described,
although it was difficult to exclude systolic unloading as a
cause of the improvement. It is emphasised that diastolic
dysfunction can exist in hypertensive heart disease, and that
the calcium antagonists nifedipine and diltiazem can improve
diastolic dysfunction.
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Subjects and methods
Abnormalities of diastolic function are now known to be a very
sensitive indicator of myocardial functional abnormalities, some-
times being detected before there are systolic abnormalities. 1,2
In patients with hypertension, in the early phases the ejection
fraction is frequently normal or high, whereas diastolic relaxa-
tion may be impaired. 3•4 Such diastolic dysfunction with
impaired left ventricular (LV) filling may theoretically explain
the early occurrence of exertional dyspnoea even at a stage
when patients still have normal systolic function as shown by a
normal ejection fraction.
Experience with calcium antagonism by nifedipine and
diltiazem when give-n acutely to patients with hypertension is
reported and the data compared with other published studies.
It is argued that normalisation of early diastolic dysfunction is
a desirable therapeutic aim.
For studies with nifedipine, 13 patients with an increased
cardiothoracic ratio on straight postero-anterior chest radio-
graphy were studied. Criteria for selection were similar to the
37 different patients studied only for ejection fraction by
]ennings et al. s Measurements were made before and 20
minutes after 10 mg nifedipine given sublingually. For studies
with diltiazem, a similar group of 11 patients (2 the same as in
the nifedipine study) was chosen (mean age 59 years, 7 women,
4 men). Measurements were made 60 minutes after admini-
stration of oral diltiazem 90 - 120 mg (60 mg to I patient, 90
mg to 6 patients, 120 mg to 4 patients; mean dose 98 mg). The
method of assessment of diastolic function by equilibrated
radionuclide angiography was similar to that used by Lavine er
al. 6 and Inouye er af.2 .
Statistical analysis. Values are expressed as mean ±
SEM. Student's r-test for paired comparisons was used with
two-tailed P values.










TABLE I. NIFEDIPINE AND RADIONUCLlDE INDICES OF LV SYSTOLlC AND DIASTOLlC
FUNCTION IN HYPERTENSION (N= 13)
Pre-nifedipine Post-nifedipine
64,8 ± 2,9 67,6 ± 3,2
182/113 ± 5/3 162/99 ± 4/3
76,3 ± 4,8 82,5 ± 3,5
3,27 ± 0,21 3,66 ± 0,27
1,94±0,16 1,98±0,14
0,34 ± 0,01 0,35 ± 0,01
2,79 ± 0,20 3,05 ± 0,31




Peak systolic ejection rate (EDV Is)
Mean systolic ejection rate (EDV Is)
Time to peak filling rate (5)
Peak diastolic filling ratet
Mean diastolic filling ratet
... From a similar but not identical group of patients (Jennings et a/. 5).


























TABLE 11. DILTlAZEM AND RADIONUCLlDE INDICES OF LV SYSTOLlC AND DIASTOLlC





Peak_systolic ejection rate (EDV Is)
Mean systC!lic ejection rate (EDV Is)
Time to peak filling rate (s)
Peak diastolic filling rate*
Mean diastolic filling rate*
if EDV/s Post-diltiazem = 50-60 min after oral diltiazem. mean about 100 mg.
TABLE Ill. NIFEDIPINE AND HYPERTROPHIC CARDIOMYOPATHY
Fractional shortening (0/0)
Heart rate (lmin)

















* LV internal dimension increase 20 min after 10 mg sublingual nifedipine.
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Fig. 2. Effect of diltiazem on arterial blood pressure after an acute
dose (90-120 mg diltiazem, average 98 mg). Note that at time of
blood pressure fall at 50 minutes post-diltiazem, both the systolic
and diastolic functions of the myocardium improved (Table 11).
Fig. 3. Effect of diltiazem on LV ejection fraction 50-60 minutes
after acute oral dose of 90-120 mg (mean, 98 mg).
Discussion
Diastolic abnormalities in hypertension
Diastolic abnormalities are now accepted as a well esta-
blished complication of hypertensive heart disease. The new
aspect of the present report is the finding that nifedipine given
sublingually improves diastolic filling within 20 minutes and
that diltiazem given orally does likewise within 60 minutes.
These findings may be interpreted in relation to the role of
other abnormalities of LV function in hypertension, as well as
a consideration of the role of LV hypertrophy in .the genesis of
such altered diastolic function.
In hypertensive hean disease, there may be abnormalities of
all phases of diastolic function, with slowing of early isovolumic
relaxation, decreased early filling, prolonged late filling, and
an increased atrial contraction phase.7 Such abnormalities have
been s~~wn .by a ~ariety. ~f methods. includiI]-~ echocardio-
graphy,' radionuclide equilibrated anglOgraphy-' and Doppler
echocardiography.8 The abnormalities of diastolic function
correlate well with the increase of LV mass2 and may be
detected before there is definite evidence of systolic cardiac
impairment. I,3 However, isolated patients have been reported
in whom abnormalities of diastolic function have been found
even when not accompanied by an increased LV mass as
measured by echocardiography.9
Diastolic function in other causes
of hypertrophy
~ important 'question is whether the abnormalities of LV
diastolic function are specific to hypertension or whether they
merely indicate "LV pressure overload. In the laner case
similar abnormalities would be expected in patients with aortic
stenosis.. Some studies suggest that the echocardiographic
abnormalities of diastolic function are similar in patients with
hypertrophic cardiomyopathy or aortic stenosis,6 hypertrophic
cardiomyopathy, and LV hypertrophy of systemic hyperten-
sion. 8, 10 Hanrath et al. 7 were able to show some differences in
diastolic function between hypertrophic cardiomyopathy and
hypertensive hypertrophy, with an increased atrial 'booster'
effect compensating bener for the abnormalities of the pressure
overloaded state. None the less these authors were unable to
make any clear distinction between these conditions and the
findings in, the one blended into those in the other. Further-
more, as they point out, it is difficult to exclude minor degrees
of ischaemia in severe hypertrophic cardiomyopathy and
ischaemia could cause delayed LV relaxation. Spirito et al. ll
found an overall link between ventricular hypertrophy in
hypertrophic cardiomyopathy, and abnormal diastolic function,
yet in some non-hypertrophied myocardial segments, there
were also abnormalities of diastolic function. Thus the links
are not absolute and the genesis of the impaired LV relaxation
may be multifactorial in origin and not only related to the
degree of LV hypertrophy.12 The cause of the hypertrophy
seems to be important in determining the abnormalities of LV
diastolic function. In athletes an increased LV mass is associated
with normal diastolic function. 3,I3 Hence these data in man
accord with animal experiments which suggest that exercise-
induced hypertrophy might be 'bener' than diseased-induced
hypertrophy from the point of view of myocardial function. 14
Role of calcium antagonist agents in
LV hypertrophy
Initial studies were in severe hypertrophic cardiomyopathy.
Hanrath et al.7 administered intravenous verapamil and found
a decrease in LV isovolumic relaxation time. Chanerjee et al. I5
reviewed the effect of calcium antagonist agents on diastolic
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function in hypertrophic cardiomyopathy, arguing for an overall
benefit on both systolic and diastolic function. Nifedipine 10
mg sublingually given to patients with hypertrophic cardio-
myopathy improved isovolumic relaxation time and LV
filling,I6 yet it is difficult to be sure that the improvements
were not a reflection of the increased heart rate. Hence our
data on hypertrophic cardiomyopathy are of interest because
diltiazem improved diastolic function while not changing the
heart rate.
Similar beneficial effects of calcium antagonists have been
described in hypertensive patients following nitrendipine4
which reverted diastolic abnormalities towards normal. It
should, however, be noted that they used the same control
groups in Tables I and II of their study, therefore invoking
multiple comparisons which should have been corrected by
the Bonferroni method,17 thereby weakening the statistical
strength of their findings. In contrast, Inouye er al. I8 found
that 4 weeks of chronic treatment with diltiazem did not alter
the peak diastolic filling rate nor the first third filling time,
although 7/10 patients improved as far as the latter parameter
is concerned. It is possible that the wide errors inherent in the
radionuclide methodology might have obscured a benefit over
4 weeks of treatment. From that point of view we feel that our
acute study, repeated in the same patients early after a single
dose of nifedipine (20 minutes) or diltiazem (60 minutes) was
designed to show up relatively fine differences. Thus our data
agree with the concept that there are diastolic abnormalities in
hypertensive hean disease and that the use of calcium antagonist
agents may help revert these abnormalities towards normal.
It might be argued that the acute hypotensive effect of
diltiazem and of nifedipine might have improved systolic
function which in turn could alter diastolic function which is
in pan dependent on systolic loading. I9 Fouad er al. 20 showed
that in hypertensive patients the maximum filling rate improved
as the maximal ejection velocity increased; however, the
increase was much less in hypertensives than in normals. A
decreased afterload, by reducing systolic loading conditions,
might also have improved early diastolic function. I9 We
therefore had no proof of a specific effect of nifedipine nor of
diltiazem on diastolic function in our hypertensive patients, as
systolic unloading could theoretically explain the improved
diastolic function. However, in our patients with hypertrophic
cardiomyopathy, improved diastolic function was found in the
absence of any increase in LV ejection fraction or change in
hean rate or blood pressure.
LV mass - the crucial link
LV hypertrophy may impair diastolic function. I,2 Even
though the link between myocardial hf.~ertrophyand diastolic
abnormalities are not absolutely tight, , 1 none the less there is
a good ove"rall correlation. Hence it is important that the
chronic use of calcium antagonists including nifedipine,
verapatnil and diltiazem has been shown to decrease LV mass
in hypertensive patients. 2I.22 In the case of nifedipine, a
decreased cardiothoracic ratio has been reported during chronic
therapy in combination with ,B-blockade and diuretics. 23
Because an increased LV mass is associated with diastolic
functional abnormalities,2 it may therefore be expected that
the acute benefit on diastolic function found in our study may
be translated into sustained benefit during prolonged nifedipine
therapy. However; proof of this attractive hypothesis is
presently lacking.
An important reservation to our study is that we did not
show that therapy with calcium antagonists was able to relieve
dyspnoea in the presence of normal systolic function. Such
exertional dyspnoea is presumably caused by diastolic dys-
function and should improve with calcium antagonist therapy.
This proposal should also be the subject of further clinical
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trials. However, an imponant possibly relevant fInding is that
in ischaemic heart disease, diastolic dysfunction relates to
exercise and tolerance independently of changes in systolic
function. 24
Nifedipine v. other calcium antagonists
Calcium antagonists are now established antihypertensive
agents. Nifedipine is among the best studied for its anti-
hypertensive effect, and it induces hypotension after 20-30
minutes of sublingual administration, accompanied by improved
systolic5 and diastolic function (present data) in our patients
with radiologic cardiomegaly. A similar degree of hypotension
was observed after 50-60 minutes following oral diltiazem in
our patients. In the case of oral verapamil, 60 minutes is also
likely to be required for the acute hypotensive effect.25 The
difference between the onset of action of nifedipine and other
agents is therefore 30 minutes or more, which can be of crucial
practical signifIcance when testing the acute hypotensive
response to a calcium antagonist in the doctor's consulting
room. 5,23
While no differences could be detected in our acute study
betwe.en the effects on diastolic function of nifedipine and
diltiazem, it should be kept in mind that patients with compli-
cated hypertension are frequently already receiving pre-existing
therapy when referred for specialised opinion. Nifedipine may
safely be combined with pre-existing ,B-blockade even when
the ejection fraction on ,B-blockade is low (mean 32% in 4
patients, increasing to 38% after nifedipine23). Haemodynami-
cally, nifedipine is easier to combine with ,B-blockade than is
verapamil or diltiazem because there is less chance of an
increase in end-diastolic volume or prolonged PR-interval as
shown in patients with ischaemic heart disease;26 similar
principles should hold for hypertensive patients. In animal
experiments, the combination of nifedipine with ,a-blockade.
caused no change in ventricular relaxation, whereas the time
constant was prolonged by the combination ,B-blockade-
verapamil. 27
Reservations
It should be pointed out that: (I) the nifedipine data on
blood pressure measurements presented in Table I were
obtained from a different study;5 (it) sublingual and not oral
nifedipine was used; and (iit) the diastolic data in Table I were
collected 30 minutes after nifedipine administration and not at
20 minutes as were the other data. The use of sublingual
nifedipine in this study can be criticised because of erratic and
poor absorption.28 However, it should be borne in mind that
in their study after the nifedipine capsule was bitten, the
contents were held in the mouth for 20 minutes before being
swallowed. In normal clinical practice, biting the capsule is
inevitably followed by swallowing at least some of the liquid
contents. In our study on a total of 80 patients,5 a consistent
hypotensive effect lasting for 20-40 minutes29 was obtained
after sublingual nifedipine. Although the omission of blood
pressure measurements in the present study could be criticised,
the consistent effect in previous studies on 80 patients5together
with an increase of the ejection fraction similar in magnitude
to that previously found, as well as the improved diastolic
function, all suggest that nifedipine given sublingually was
active in the present study. Because of the prolonged hypo-
tensive effect of nifedipine given sublingually,29 the disctepancy
between the studies done at 30 minutes after nifedipine (dia-
stolic function) and those done at 20 minutes (systolic function)
would appear not to be serious. None the less, such dis-.
crepancies in the timing should be considered if precise inter-
pretation of the timing of the data is crucial.
Clinical application
Diastolic dysfunction in hypertension may present as
impaired left ventricular filling with exertional dyspnoea and
pulmonary congestion. Besides diuretics, calcium antagonists
(usually contraindicated in congestive heart failure with major
systolic dysfunction) may be used to decrease blood pressure
and improve myocardial function. Digitalis compounds such
as digoxin are not appropriate therapy for diastolic dysfunction
and should be avoided.
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